S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Did SOFI Technologies Deserve a Price Target Cut to $2.50?
Is Graphite the New Lithium? (Ad)
10 Ways Entrepreneurs Can Navigate a Down Economy
Stock market today: Global shares mixed as investors await debt ceiling vote, eye China economy
Is Graphite the New Lithium? (Ad)
Workday: Another AI Winner Melting-Up 
Economic boost or big business hand-out? Nevada lawmakers consider A's stadium financing
The Graphite Shortage Story You're Not Being Told (Ad)
Taiwan Semiconductor Well Positioned for the AI Rush
Krystal Clear: Krystal Biotech Clears Resistance in Good Volume
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Did SOFI Technologies Deserve a Price Target Cut to $2.50?
Is Graphite the New Lithium? (Ad)
10 Ways Entrepreneurs Can Navigate a Down Economy
Stock market today: Global shares mixed as investors await debt ceiling vote, eye China economy
Is Graphite the New Lithium? (Ad)
Workday: Another AI Winner Melting-Up 
Economic boost or big business hand-out? Nevada lawmakers consider A's stadium financing
The Graphite Shortage Story You're Not Being Told (Ad)
Taiwan Semiconductor Well Positioned for the AI Rush
Krystal Clear: Krystal Biotech Clears Resistance in Good Volume
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Did SOFI Technologies Deserve a Price Target Cut to $2.50?
Is Graphite the New Lithium? (Ad)
10 Ways Entrepreneurs Can Navigate a Down Economy
Stock market today: Global shares mixed as investors await debt ceiling vote, eye China economy
Is Graphite the New Lithium? (Ad)
Workday: Another AI Winner Melting-Up 
Economic boost or big business hand-out? Nevada lawmakers consider A's stadium financing
The Graphite Shortage Story You're Not Being Told (Ad)
Taiwan Semiconductor Well Positioned for the AI Rush
Krystal Clear: Krystal Biotech Clears Resistance in Good Volume
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Did SOFI Technologies Deserve a Price Target Cut to $2.50?
Is Graphite the New Lithium? (Ad)
10 Ways Entrepreneurs Can Navigate a Down Economy
Stock market today: Global shares mixed as investors await debt ceiling vote, eye China economy
Is Graphite the New Lithium? (Ad)
Workday: Another AI Winner Melting-Up 
Economic boost or big business hand-out? Nevada lawmakers consider A's stadium financing
The Graphite Shortage Story You're Not Being Told (Ad)
Taiwan Semiconductor Well Positioned for the AI Rush
Krystal Clear: Krystal Biotech Clears Resistance in Good Volume
NASDAQ:AMED

Amedisys (AMED) Stock Forecast, Price & News

$77.31
+0.56 (+0.73%)
(As of 05/26/2023 04:00 PM ET)
Compare
Today's Range
$76.18
$77.60
50-Day Range
$69.79
$81.06
52-Week Range
$69.36
$131.32
Volume
163,500 shs
Average Volume
911,022 shs
Market Capitalization
$2.52 billion
P/E Ratio
22.47
Dividend Yield
N/A
Price Target
$108.94

Amedisys MarketRank™ Forecast

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
40.9% Upside
$108.94 Price Target
Short Interest
Bearish
8.20% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.61
Upright™ Environmental Score
News Sentiment
0.98mentions of Amedisys in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$510,628 Sold Last Quarter
Proj. Earnings Growth
9.41%
From $4.25 to $4.65 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.87 out of 5 stars

Medical Sector

38th out of 1,009 stocks

Home Health Care Services Industry

4th out of 7 stocks


AMED stock logo

About Amedisys (NASDAQ:AMED) Stock

Amedisys, Inc. engages in the provision of healthcare services. It operates through the following business segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment delivers services in the homes of individuals who may be recovering from an illness, injury, or surgery. The Hospice segment provides care that is designed to provide comfort and support for those who are facing a terminal illness. The Personal Care segment gives patients assistance with the essential activities of daily living. The High Acuity Care segment includes providing home care recovery for high acuity patients on either a full risk or limited risk basis. The company was founded in 1982 and is headquartered in Baton Rouge, LA.

Receive AMED Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amedisys and its competitors with MarketBeat's FREE daily newsletter.

AMED Stock News Headlines

Amedisys (NASDAQ:AMED) Coverage Initiated at StockNews.com
Is Graphite the New Lithium?
Did you know that graphite (NOT lithium) is the largest component of lithium batteries used for EV's? Unfortunately, there are no graphite-producing mines in North America today. This leaves the U.S. at the mercy of China for our vital graphite supply.
Amedisys, Inc. (NASDAQ:AMED) Short Interest Update
The Graphite Shortage Story You're Not Being Told
Graphite demand for EV batteries is expected to increase 10X from 2020 to 2030. And today, with NO graphite-producing mines in N. America, China has a stranglehold on our graphite supply. That's why the U.S. government is spending billions of dollars to ensure an adequate domestic supply of this metal that's vital for energy independence and national security.
Amedisys (NASDAQ:AMED) PT Lowered to $88.00 at Barclays
Amedisys (AMED) to Release Quarterly Earnings on Wednesday
See More Headlines
Receive AMED Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amedisys and its competitors with MarketBeat's FREE daily newsletter.

AMED Company Calendar

Last Earnings
5/04/2023
Today
5/30/2023
Next Earnings (Estimated)
7/26/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Home health care services
Sub-Industry
Health Care Services
Sector
Medical
Current Symbol
NASDAQ:AMED
CUSIP
02343610
Employees
20,000
Year Founded
1982

Price Target and Rating

Average Stock Price Forecast
$108.94
High Stock Price Forecast
$165.00
Low Stock Price Forecast
$81.00
Forecasted Upside/Downside
+40.9%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
15 Analysts

Profitability

Net Income
$118.61 million
Pretax Margin
6.77%

Debt

Sales & Book Value

Annual Sales
$2.22 billion
Cash Flow
$7.25 per share
Book Value
$34.06 per share

Miscellaneous

Free Float
31,875,000
Market Cap
$2.52 billion
Optionable
Optionable
Beta
1.02

Social Links


Key Executives

  • Richard M. Ashworth
    President & Chief Executive Officer
  • Scott G. GinnScott G. Ginn
    Chief Operating & Financial Officer & EVP
  • Michael P. NorthMichael P. North
    Chief Information Officer
  • Denise M. BohnertDenise M. Bohnert
    Chief Compliance Officer
  • Kendra Kimmons
    Vice President-Marketing & Communications













AMED Stock - Frequently Asked Questions

Should I buy or sell Amedisys stock right now?

15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amedisys in the last year. There are currently 2 sell ratings, 6 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" AMED shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMED, but not buy additional shares or sell existing shares.
View AMED analyst ratings
or view top-rated stocks.

What is Amedisys' stock price forecast for 2023?

15 equities research analysts have issued 12 month target prices for Amedisys' stock. Their AMED share price forecasts range from $81.00 to $165.00. On average, they predict the company's stock price to reach $108.94 in the next twelve months. This suggests a possible upside of 40.9% from the stock's current price.
View analysts price targets for AMED
or view top-rated stocks among Wall Street analysts.

How have AMED shares performed in 2023?

Amedisys' stock was trading at $83.54 at the beginning of 2023. Since then, AMED stock has decreased by 7.5% and is now trading at $77.31.
View the best growth stocks for 2023 here
.

When is Amedisys' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, July 26th 2023.
View our AMED earnings forecast
.

How were Amedisys' earnings last quarter?

Amedisys, Inc. (NASDAQ:AMED) announced its quarterly earnings results on Thursday, May, 4th. The health services provider reported $1.00 EPS for the quarter, topping analysts' consensus estimates of $0.86 by $0.14. The health services provider earned $556.39 million during the quarter, compared to analyst estimates of $558.98 million. Amedisys had a trailing twelve-month return on equity of 14.35% and a net margin of 5.02%. The business's revenue for the quarter was up 2.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.23 earnings per share.

How will Amedisys' stock buyback program work?

Amedisys declared that its board has initiated a stock buyback program on Wednesday, August 4th 2021, which authorizes the company to buyback $100,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization authorizes the company to reacquire up to 1.2% of its stock through open market purchases. Stock buyback programs are often a sign that the company's leadership believes its stock is undervalued.

What guidance has Amedisys issued on next quarter's earnings?

Amedisys issued an update on its FY 2023 earnings guidance on Wednesday, May, 3rd. The company provided earnings per share guidance of $4.14-$4.36 for the period, compared to the consensus earnings per share estimate of $4.25. The company issued revenue guidance of $2.25 billion-$2.27 billion, compared to the consensus revenue estimate of $2.26 billion.

What is Paul B. Kusserow's approval rating as Amedisys' CEO?

478 employees have rated Amedisys Chief Executive Officer Paul B. Kusserow on Glassdoor.com. Paul B. Kusserow has an approval rating of 79% among the company's employees. 60.0% of employees surveyed would recommend working at Amedisys to a friend.

What other stocks do shareholders of Amedisys own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amedisys investors own include NVIDIA (NVDA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Pfizer (PFE), Adobe (ADBE), Intel (INTC), QUALCOMM (QCOM), Broadcom (AVGO), Cisco Systems (CSCO) and Home Depot (HD).

What is Amedisys' stock symbol?

Amedisys trades on the NASDAQ under the ticker symbol "AMED."

Who are Amedisys' major shareholders?

Amedisys' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (9.33%), Wellington Management Group LLP (7.98%), JPMorgan Chase & Co. (6.13%), Riverbridge Partners LLC (4.69%), Mackenzie Financial Corp (3.20%) and State Street Corp (2.83%). Insiders that own company stock include Bruce D Perkins, Bruce D Perkins, Christopher Gerard, David L Kemmerly, David L Kemmerly, Denise M Bohnert, Michael Paul North, Richard A Lechleiter, Scott G Ginn and Sharon Brunecz.
View institutional ownership trends
.

How do I buy shares of Amedisys?

Shares of AMED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amedisys' stock price today?

One share of AMED stock can currently be purchased for approximately $77.31.

How much money does Amedisys make?

Amedisys (NASDAQ:AMED) has a market capitalization of $2.52 billion and generates $2.22 billion in revenue each year. The health services provider earns $118.61 million in net income (profit) each year or $3.44 on an earnings per share basis.

How many employees does Amedisys have?

The company employs 20,000 workers across the globe.

How can I contact Amedisys?

Amedisys' mailing address is 3854 AMERICAN WAY SUITE A, BATON ROUGE LA, 70816. The official website for the company is www.amedisys.com. The health services provider can be reached via phone at (225) 292-2031, via email at ir@amedisys.com, or via fax at 225-292-8163.

This page (NASDAQ:AMED) was last updated on 5/30/2023 by MarketBeat.com Staff

My Account -